INS and type 2 diabetes mellitus: Oral hypoglycemic agents used to manage T2D employ various mechanisms of action that trigger different physiological responses; they either activate or inhibit drug receptors to improve insulin sensitivity, increase insulin secretion, block glucose absorption, or decrease glucose production [6].